View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 13, 2022

FDA grants approval for BioCardia’s Covid-19 stem cell therapy trial

The initial portion of the trial will assess increasing doses of the NK1R+ MSCs in adult patients.

The US Food and Drug Administration (FDA) has granted clearance to BioCardia’s Investigational New Drug (IND) application to commence a Phase I/II clinical trial of BCDA-04 in adults recovering from Covid-19-linked acute respiratory distress syndrome (ARDS).

An investigational cell therapy, BCDA-04 is a Neurokinin-1 receptor-positive (NK1R+) allogeneic mesenchymal cell (MSC) population.

With the latest approval, the company intends to commence the first-in-human trial in the third quarter of this year.

The initial portion of the trial will assess increasing doses of the NK1R+ MSCs and the optimal dose will be chosen for the randomised Phase II trial in adult subjects recovering from Covid-19-linked ARDS.

BioCardia chief scientific officer Ian McNiece said: “This investigational cell therapy is administered intravenously (IV) and follows a significant body of compelling clinical results by NIH investigators and peer companies. 

“After IV delivery, the cells migrate to the lungs for local therapeutic benefit. 

“We expect the anti-inflammatory nature of these mesenchymal stem cells to have a positive impact in ARDS because of the interaction of the Neurokinin-1 receptors with Substance P, a neuropeptide that has long been known to be a primary mediator of inflammation in the lungs.”

BioCardia focuses on the development of cellular and cell-derived therapies to treat cardiovascular and pulmonary diseases. 

Fluid accumulation in the tiny, elastic air sacs called alveoli in the lungs causes ARDS. The fluid keeps the lungs from filling with air, which results in less oxygen reaching the bloodstream. 

This deprives organs of the oxygen required for them to work properly.

Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena